Bristol Buys DuPont: Re-Enters Imaging Agents, Adds To HIV Line
Executive Summary
Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.
You may also be interested in...
Deals Of The Week Untangles The String Of Pearls
In light of rumors that Bristol-Myers Squibb is looking to buy a major biopharma, DOTW evaluates the role deal-making has played in the company’s rebuilding since it implemented its “string-of-pearls” strategy in 2007. Plus updates on Celgene/Presage, Array/Global Blood Therapeutics, Targacept/AstraZeneca and more.
Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts
Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City
Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts
Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City